InvestSMART

Cardiex Limited (ASX:CDX)

ALERT: Price-sensitive ASX Announcement for CDX
Current share price for CDX : $0.036 0.005 (16.13%)+
Announcement
Release
29 Aug 2025 4:13PM
Price at Release
$0.031
Full Release
download
Summary
Cardiex Limited announced its FY25 Preliminary Results, highlighting a 10% increase in revenue despite excluding $7.7 million from Clinichain recorded in FY24. This growth was supported by the introduction of the Pulse in the second half of FY25. Significant operational streamlining resulted in a reduced annual expense base of $10-$12 million, excluding COGS and marketing. As of 30 June 2025, Cardiex had $2.4 million in cash, with additional inflows expected from a June placement and R&D Incentive cash rebate. Net assets grew by 37% to $5.6 million. C2 Ventures confirmed its full participation in the June Placement, indicating further capital support, thereby strengthening Cardiex's position to pursue its FY26 growth strategy.
Key Points
  • Cardiex reported a 10% revenue increase in FY25.
  • The company launched the Pulse product in H2 FY25.
  • Operational cost reductions significantly lowered the annual expense base.
  • Cash at hand by 30 June 2025 was $2.4 million, with more expected inflows.
  • Net assets increased by 37% to $5.6 million.
  • C2 Ventures confirmed full participation in the June Placement.
  • The company is positioned to execute its FY26 growth strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.